4//SEC Filing
Kennedy Paul F. 4
Accession 0001181431-09-017801
CIK 0001095858other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 4:13 PM ET
Size
14.4 KB
Accession
0001181431-09-017801
Insider Transaction Report
Form 4
Debregeas Patrice
Director10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2009-03-27$0.70/sh−1,500,000$1,050,000→ 2,800,000 total - Purchase
Common Stock, $0.01 par value
2009-03-27$0.70/sh+1,500,000$1,050,000→ 14,350,000 total
Holdings
- 2,850,000(indirect: By LLC)
Common Stock, $0.01 par value
- 2,850,000
Common Stock, $0.01 par value
- 14,350,000(indirect: By Debregeas & Associes Pharma SAS)
Common Stock, $0.01 par value
Debregeas & Associes Pharma SAS
10% Owner
Transactions
- Purchase
Common Stock, $0.01 par value
2009-03-27$0.70/sh+1,500,000$1,050,000→ 14,350,000 total - Sale
Common Stock, $0.01 par value
2009-03-27$0.70/sh−1,500,000$1,050,000→ 2,800,000 total
Holdings
- 14,350,000(indirect: By Debregeas & Associes Pharma SAS)
Common Stock, $0.01 par value
- 2,850,000(indirect: By LLC)
Common Stock, $0.01 par value
- 2,850,000
Common Stock, $0.01 par value
Kennedy Paul F.
Director10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2009-03-27$0.70/sh−1,500,000$1,050,000→ 2,800,000 total - Purchase
Common Stock, $0.01 par value
2009-03-27$0.70/sh+1,500,000$1,050,000→ 14,350,000 total
Holdings
- 14,350,000(indirect: By Debregeas & Associes Pharma SAS)
Common Stock, $0.01 par value
- 2,850,000
Common Stock, $0.01 par value
- 2,850,000(indirect: By LLC)
Common Stock, $0.01 par value
Umbria LLC
10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2009-03-27$0.70/sh−1,500,000$1,050,000→ 2,800,000 total - Purchase
Common Stock, $0.01 par value
2009-03-27$0.70/sh+1,500,000$1,050,000→ 14,350,000 total
Holdings
- 14,350,000(indirect: By Debregeas & Associes Pharma SAS)
Common Stock, $0.01 par value
- 2,850,000(indirect: By LLC)
Common Stock, $0.01 par value
- 2,850,000
Common Stock, $0.01 par value
Footnotes (5)
- [F1]On March 27, 2009, Debregeas & Associes Pharma SAS and Paul F. Kennedy entered into a stock purchase agreement, pursuant to which Debregeas & Associes Pharma SAS agreed to purchase from Paul F. Kennedy 1,500,000 shares of the issuer's common stock at a purchase price of $0.70 per share.
- [F2]These shares of the issuer's common stock are directly owned solely by Debregeas & Associes Pharma SAS and indirectly owned by Patrice Debregeas, who may be deemed to control Debregeas & Associes Pharma SAS.
- [F3]These shares of the issuer's common stock are directly owned solely by Paul F. Kennedy.
- [F4]These shares of the issuer's common stock are directly owned solely by Umbria LLC and indirectly owned by Paul F. Kennedy, the sole equity owner of Umbria LLC.
- [F5]Debregeas & Associes Pharma SAS, Patrice Debregeas, Paul F. Kennedy and Umbria LLC comprise a "group" under Section 13(d) of the Securities Exchange Act of 1934, as amended, with respect to their ownership of shares of the issuer's common stock.
Documents
Issuer
IVAX DIAGNOSTICS INC
CIK 0001095858
Entity typeother
Related Parties
1- filerCIK 0001444812
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 4:13 PM ET
- Size
- 14.4 KB